中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
7期
685-688
,共4页
晚期非小细胞肺癌%培美曲塞%多西他赛%顺铂
晚期非小細胞肺癌%培美麯塞%多西他賽%順鉑
만기비소세포폐암%배미곡새%다서타새%순박
Advanced non-small-cell lung cancer%Pemetrexed%Docetaxel%Cisplatin
目的 比较培美曲塞与多西他赛联合铂类一线治疗晚期非小细胞肺癌(NSCLC)的效果及毒副反应.方法 102例晚期NSCLC患者随机分为培美曲塞+顺铂(PC)组52例和多西他赛+顺铂(TP)组50例.PC组:培美曲塞500 mg/m2静脉滴注,第1天；顺铂75 mg/m2静脉滴注,第1～3天.TP组:多西他赛75 mg/m2静脉滴注,第1天；顺铂75 mg/m2静脉滴注,第1～3天.两组均21 d为1周期.比较两组疾病控制率、无进展生存期、中位生存期和1年生存率.结果 102例患者均可评价疗效及毒副反应,无完全缓解病例,部分缓解43例,稳定38例,进展21例.PC组与TP组的疾病控制率[80.8％(42/52)与78.0％ (39/50)]、无进展生存期(5.69个月与4.71个月,P=0.334)、中位生存期(10.49个月与10.48个月,P=0.851)和1年生存率(32.0％与24.0％,x2=1.59,P=0.210)差异均无统计学意义.两组的不良反应主要为骨髓抑制和消化道反应,培美曲塞可致白细胞数下降(P =0.010)、脱发(P=0.004)、发热(P =0.024)、皮疹(P =0.048),两组比较差异均有统计学意义；而两组在贫血(P =0.873)、血小板减少(P=0.541)、恶心/呕吐(P=0.114)、肝毒性(P=0.403)、肾毒性(P=0.541),两组差异无统计学意义.结论 培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的临床疗效相当,但可降低毒副反应发生率.
目的 比較培美麯塞與多西他賽聯閤鉑類一線治療晚期非小細胞肺癌(NSCLC)的效果及毒副反應.方法 102例晚期NSCLC患者隨機分為培美麯塞+順鉑(PC)組52例和多西他賽+順鉑(TP)組50例.PC組:培美麯塞500 mg/m2靜脈滴註,第1天；順鉑75 mg/m2靜脈滴註,第1～3天.TP組:多西他賽75 mg/m2靜脈滴註,第1天；順鉑75 mg/m2靜脈滴註,第1～3天.兩組均21 d為1週期.比較兩組疾病控製率、無進展生存期、中位生存期和1年生存率.結果 102例患者均可評價療效及毒副反應,無完全緩解病例,部分緩解43例,穩定38例,進展21例.PC組與TP組的疾病控製率[80.8％(42/52)與78.0％ (39/50)]、無進展生存期(5.69箇月與4.71箇月,P=0.334)、中位生存期(10.49箇月與10.48箇月,P=0.851)和1年生存率(32.0％與24.0％,x2=1.59,P=0.210)差異均無統計學意義.兩組的不良反應主要為骨髓抑製和消化道反應,培美麯塞可緻白細胞數下降(P =0.010)、脫髮(P=0.004)、髮熱(P =0.024)、皮疹(P =0.048),兩組比較差異均有統計學意義；而兩組在貧血(P =0.873)、血小闆減少(P=0.541)、噁心/嘔吐(P=0.114)、肝毒性(P=0.403)、腎毒性(P=0.541),兩組差異無統計學意義.結論 培美麯塞與多西他賽聯閤順鉑治療晚期肺腺癌的臨床療效相噹,但可降低毒副反應髮生率.
목적 비교배미곡새여다서타새연합박류일선치료만기비소세포폐암(NSCLC)적효과급독부반응.방법 102례만기NSCLC환자수궤분위배미곡새+순박(PC)조52례화다서타새+순박(TP)조50례.PC조:배미곡새500 mg/m2정맥적주,제1천；순박75 mg/m2정맥적주,제1～3천.TP조:다서타새75 mg/m2정맥적주,제1천；순박75 mg/m2정맥적주,제1～3천.량조균21 d위1주기.비교량조질병공제솔、무진전생존기、중위생존기화1년생존솔.결과 102례환자균가평개료효급독부반응,무완전완해병례,부분완해43례,은정38례,진전21례.PC조여TP조적질병공제솔[80.8％(42/52)여78.0％ (39/50)]、무진전생존기(5.69개월여4.71개월,P=0.334)、중위생존기(10.49개월여10.48개월,P=0.851)화1년생존솔(32.0％여24.0％,x2=1.59,P=0.210)차이균무통계학의의.량조적불량반응주요위골수억제화소화도반응,배미곡새가치백세포수하강(P =0.010)、탈발(P=0.004)、발열(P =0.024)、피진(P =0.048),량조비교차이균유통계학의의；이량조재빈혈(P =0.873)、혈소판감소(P=0.541)、악심/구토(P=0.114)、간독성(P=0.403)、신독성(P=0.541),량조차이무통계학의의.결론 배미곡새여다서타새연합순박치료만기폐선암적림상료효상당,단가강저독부반응발생솔.
Objective To investigate the clinical efficacy and toxicity of comparison of the pemetrexed combined with cisplatin and docetaxel of advanced non small cell lung cancer(NSCLC).Methods The clinical data of 102 patients with advanced NSCLC were retrospectively analyzed.Fifty-two patients received pemetrexed combined with cisplatin (Group PC) (pemetrexed 500 mg/m2 intravenous drip in first day,cisplatin 75 mg/m2,intravenous drip in first day to third day,repeated every 21 days); Other 50 patients received the docetaxel combined with cisplatin (Group TP) (docetaxel 75 mg/m2 intravenous drip in first day,cisplatin 75 mg/m2 ntravenous drip in first day to third day,repeated every 21 days).The disease control rate (DCR),progress free survival,median survival time and 1 year survival rate were compared between two groups.Results The efficacy and side effects of all the patients could be evaluated.There was no case with complete remission,43 of partial remission,38 cases of stable and 21 cases of progress.No statistical significance were found between the two groups in DCR (80.8％ (42/52) vs.78.0％ (39/50)),progression-free survival (5.69 vs.4.71 months,P =0.334),median survival time (10.49 vs.10.48 months,P =0.851) and 1 year survival rate (32.0％ vs.24.0％,x2 =1.59,P =0.210).The most common toxicities were arrest of bone marrow and alimentary tract reactions.Pemetrexed could reduce the Leukopenia (P =0.010),the alopecia (P =0.004),the febrile (P =0.024) and tetter (P =0.048); but no significant difference was found in anaemia (P =0.873),thrombocytopenia (P =0.541),nausea and vomiting (P =0.114) and impaired liver function (P =0.403) and impaired renal function (P =0.541).Conclusion Pemetrexed and docetaxel combined with cisplatin for the treatment of advanced NSCLC have similar treatment effects,and the side effect of pemetrexed combined cisplatin is lower.
